We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers
Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
Data Provided by Refinitiv. Minimum 15 minutes delayed.
06-23-2021 3:20 PM EDT
06-08-2021 3:50 PM EDT
03-09-2021 7:00 AM EST